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Background: Amblyopia (lazy eye) affects the vision of approximately 2% of all children. Traditional treatment
consists of wearing a patch over their ‘good’ eye for a number of hours daily, over several months. This treatment is
unpopular and compliance is often low. Therefore results can be poor. A novel binocular treatment which uses 3D
technology to present specially developed computer games and video footage (I-BiT™) has been studied in a small
group of patients and has shown positive results over a short period of time. The system is therefore now being
examined in a randomised clinical trial.
Methods/design: Seventy-five patients aged between 4 and 8 years with a diagnosis of amblyopia will be
randomised to one of three treatments with a ratio of 1:1:1 - I-BiT™ game, non-I-BiT™ game, and I-BiT™ DVD. They
will be treated for 30 minutes once weekly for 6 weeks. Their visual acuity will be assessed independently at baseline,
mid-treatment (week 3), at the end of treatment (week 6) and 4 weeks after completing treatment (week 10).
The primary endpoint will be the change in visual acuity from baseline to the end of treatment. Secondary
endpoints will be additional visual acuity measures, patient acceptability, compliance and the incidence of adverse
events.
Discussion: This is the first randomised controlled trial using the I-BiT™ system. The results will determine if the
I-BiT™ system is effective in the treatment of amblyopia and will also determine the optimal treatment for future
development.
Trial registration: ClinicalTrials.gov identifier: NCT01702727
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Amblyopia occurs when normal visual experience is
disrupted during the critical periods for visual develop-
ment. It most commonly presents in association with
strabismus, anisometropia or both. Several forms of
treatment for amblyopia exist but occlusion treatment is
the gold standard and involves covering the good eye
with a patch for a prescribed period of time each day
[1]. The length of patching treatment varies and ranges
from 10 minutes daily to all waking hours [2]. The child
must wear the patch at home or school and typically,
120 hours of patching treatment results in 1 LogMAR
line of improvement in visual acuity [3]. Treatment is
prolonged and this contributes to poor compliance.
Many children refuse to wear their patch for the pre-
scribed time and this is a major cause of failure of treat-
ment. Many children feel they are stigmatised by the
wearing of a patch. Dixon-Woods et al. [4] reported
patching caused distress and other negative outcomes
such as relationship strain. In extreme cases, non-
compliance with patching can result in a child having a
costly admission to hospital to have supervised patching
treatment. In addition, wearing a patch prevents both
eyes being used at the same time which eliminates any
advantage of binocularity (using the two eyes together as
a pair).
Other forms of amblyopia treatment are used such as
atropine eye drops and optical penalisation. These are
usually chosen as secondary treatments if patching fails,
and act by reducing the vision of the good eye in order
that the child uses the amblyopic eye to see. All the
existing traditional treatments rely on penalisation of
the good eye with either a patch, eye drops or through
the use of lenses (optical penalisation).
As an alternative to this treatment, we have developed
a virtual reality-based system to treat amblyopia where
children play special video games and watch DVDs. This
interactive binocular treatment system (I-BiT™) uses spe-
cially configured software to preferentially stimulate the
amblyopic eye without compromising the vision in the
good eye. The treatment activity is designed to be enjoy-
able and, importantly, the child does not have to suffer
the unpleasant experience of having their vision limited
by the sole use of their amblyopic eye (as they do with
patching). The treatment has so far been delivered in the
hospital eye clinic but the I-BiT system has the potential
to be further developed for use in the home environ-
ment in the future.
Previous pilot studies [5] have shown the I-BiT™ sys-
tem to be highly effective in improving the visual acuity
in amblyopic patients. Since we first began our studies,
3D technology has improved and we have recently
conducted a pilot study to assess delivery of I-BiT™ treat-
ment using the latest generation of shutter glassestechnology [6]. This study showed that all patients who
completed their planned treatment (9 of the 10 patients)
showed an improvement in visual acuity. These im-
provements ranged from 0.025 to 0.45 LogMAR units
with a mean of 0.18 (sd 0.143) and a median of 0.175.
While the study did have limitations (it was uncon-
trolled, unblinded and the sample size was small) the re-
sults were promising and warranted further investigation
in a randomised controlled study. This study will aim to
compare the effect of the I-BiT™ game with the I-BiT™
DVD and also to compare the effect of the I-BiT™ game
with a control in which the patient plays the game without
the amblyopic eye being preferentially stimulated.
Methods/design
Objectives of the study
The primary objective of the study is to investigate
whether there is any difference in visual acuity in pa-
tients treated with I-BiT™ versus non-I-BiT™ and also if
there is any difference between the two treatment
stimuli (interactive game versus DVD). Therefore two
comparisons will be made: differentiation of the type
of I-BiT™ treatment and differentiation of I-BiT™ from
non-I-BiT™.
Secondary objectives include examining visual acuity
at additional time points (mid-treatment and 4 weeks
after treatment has stopped), investigating the propor-
tion of patients showing a response to treatment (a
change from baseline of 0.125 or more [7]), the propor-
tion of change in visual acuity, the change in binocular
function, the acceptability of the treatment to the pa-
tient, compliance with treatment, and the safety profile
of the treatment.
I-BiT™ shutter glasses system
The I-BiT™ system hardware consists of a desktop PC
with two monitors, one for the clinician and one for the
patient. As with all previous I-BiT™ system prototypes,
the clinician monitor is used to control the treatment
the patient receives and the patient monitor displays the
visual stimuli. The system uses 3D shutter glasses and
their corresponding infra-red emitter. The patient moni-
tor is a flat-screen 18-inch 3D monitor with a refresh
rate of 120 Hz as required for use with the shutter
glasses. The shutter glasses lenses lighten and darken in
synchrony with the monitor but faster than the user can
perceive. The patient sits on a comfortable gaming bean-
bag for the duration of their treatment.
This I-BiT™ system relies on the same principle as pre-
vious prototypes [8]. Images are presented to both eyes
but parts of the image are presented only to the ambly-
opic eye. The visual scene with the I-BiT™ system is not
presented stereoscopically. Instead the 3D technology is
used to present a distinct but visually related image to
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dimensional visual scene. The I-BiT™ system can display
video footage and interactive games. A gaming control
pad is used for the games. The games have been specific-
ally developed to appeal to children aged 8 years and
under. The visual stimuli presented in the current study
are described below.
Video stimulus
The principle employed is that the image is divided into
two zones. There is an outer ‘border’ termed a locking
stimulus which is presented to both eyes while the inner
part of the screen presents the video footage to the ambly-
opic eye. Images within the border can be selectively
shown to either eye to act as a control to ensure binocular
viewing. The DVD transparency settings for the non-
amblyopic eye can be adjusted for those with dense
suppression if required. This is to encourage continued
viewing and fixation with the amblyopic eye. To increase
compliance the I-BiT system has a built in DVD player and
this allows children to watch a DVD of their own choice.
Game stimulus
An interactive game called ‘Nux’ will be used to provide
the game-play. In Nux, a player moves through a colourful
two-dimensional space-like environment. Points are
rewarded for collecting coins and shooting enemies and
deducted for colliding with enemies and obstacles (for ex-
ample, asteroids). Through the I-BiT™ system, the player
and the background are shown to both eyes but the obsta-
cles, enemies and coins are shown only to the amblyopic
eye. Therefore, in order for the child to play the game suc-
cessfully, they must use their amblyopic eye. If the patient
is unable to play due to dense suppression or severely re-
duced visual acuity in their amblyopic eye then theEligible patients randomi
following
Week 1 I-BiT Game Non-I-BiT Ga
Week 3 Interim assess
Week 6 End of treatmen
End of treatment a
Week 10
End of follow-u
End of follow-up a
Full orthoptic as
Figure 1 Outline of study procedures.settings can be adjusted so that a proportion of the objects
(coins and so on.) are seen by the non-amblyopic eye. In
the non-I-BiT game version (control arm) both eyes re-
ceive identical stimulation.
Design
The study is a randomised parallel group, double-
masked design. Eligible patients are randomised to one
of three treatments:
 I-BiT™ game
 Non-I-BiT™ game
 I-BiT™ DVD
They will receive their randomised treatment weekly
for 6 weeks, for a 30-minute period (Figure 1). Their vis-
ual acuity will be assessed pre-treatment, after three
treatments, after six treatments and 4 weeks after their
final treatment. Visual acuity will be assessed by an inde-
pendent assessor who has no knowledge of the
randomised treatment. The orthoptist treating the pa-
tient will have no knowledge of the results of the pa-
tient’s visual acuity assessments. The study is therefore
masked.
Two comparisons are to be made: I-BiT™ game vs.
non-I-BiT™ game and I-BiT™ game vs. I-BiT™ DVD.
Eligibility criteria
Inclusion criteria
 Diagnosis of anisometropic, strabismic or mixed
amblyopia as made by an orthoptist (difference of 2
LogMAR units or more using a LogMAR crowded
test)
 Male or femalesed to one of the 
me I-BiT DVD 
ment
t period
ssessment
p period 
ssessment
sessment 
All patients followed 
up for 4 weeks
Patients receive 30 mins  
treatment weekly
Patients receive 30 mins 
treatment weekly
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 Participant’s parent or guardian is willing and able to
give informed consent for participation in the study
Exclusion criteria
The participant may not enter the study if any of the
following apply:
 Stimulus deprivation amblyopia
 Organic lesions of the eye preventing the
establishment of good vision (for example, media
opacities, abnormalities in the fundus or optic nerve)
 Lesions of the brain preventing the establishment of
good vision (for example, cortical visual impairment)
 Patients diagnosed with photosensitive epilepsy
 Patients diagnosed with or suspected of having
conjunctivitis
 Loss of suppression at filter 4 or less as measured
with the Sbisa bar
 Establishment of normal vision by refractive
adaptation (wearing glasses after presentation)
 Inability to comply with the follow-up visits required
 Refusal to accept randomisation
 Have participated in a previous study examining
I-BiT™ treatment
Study procedures
Screening and eligibility assessments
Potential participants will be identified by various
methods including identification by members of the clin-
ical team or by contacts made through the website and
via posters in clinic. Informed consent will be obtained
and eligibility assessed.
Baseline assessments
A full orthoptic assessment a maximum of 1 month
prior to the start of the study must be available/
performed. This assessment must include:
 Uniocular assessment of visual acuity with a
LogMAR test (aided with glasses if applicable)
 Cover test (with and without glasses if applicable)
 Ocular motility
 Assessment of binocular functions
 Visuscope assessment
 Sbisa bar (if applicable)
Randomisation and codebreaking
Subject numbers will be assigned sequentially as each
subject enters the study. The subjects will be assigned to a
study treatment arm through an independently-developed
web-based randomisation system. Randomisation will be
performed after eligibility has been checked prior to first
treatment, and will be equal and stratified according towhether the patient has had previous treatment for their
amblyopia. The research orthoptist will be the only
member of the study team who will have knowledge of
the randomised treatment.
Subsequent assessments
Patients will receive their randomised treatment for
30 min each week for 6 weeks. In addition to their
baseline assessment, they will have assessments at the
following visits, all performed by an independent assessor.
Week 1 (pre-treatment)
Uniocular assessment of visual acuity with a LogMAR test
(aided with glasses if applicable) prior to first treatment.
Week 3 (mid-treatment)
Uniocular assessment of visual acuity with a LogMAR test
(aided with glasses if applicable) after third treatment.
If at this visit, visual acuity in the amblyopic eye has
regressed by 0.1 LogMAR units or more, then the partic-
ipants should be withdrawn from the study.
Week 6 (end of treatment)
Uniocular assessment of visual acuity with a LogMAR test
(aided with glasses if applicable) after sixth treatment.
Week 10 (follow-up)
Full orthoptic assessment.
The independent assessor may perform additional
tests such as the Sbisa bar and Frisby test if clinically in-
dicated. The research orthoptist will record details of the
treatment at each visit and ascertain whether the patient
has had any adverse events.
At week 10 (follow-up), participation in the study will
be complete for the patient and they will be returned to
the care of the orthoptic department. Patients with re-
sidual amblyopia will receive standard treatment in line
with departmental guidelines.
The patient may be withdrawn from the study at any
point at the clinician’s discretion.
Outcomes
Primary outcome
The primary variable is visual acuity. Visual acuity is
measured in units of 0.025 (which equates to one letter).
Improvement in visual acuity is measured as an increase
of 0.025 LogMAR units.
The primary endpoint is the change from baseline to
the end of treatment (6 weeks) in visual acuity.
The secondary endpoints are:
 Change in visual acuity from baseline to the end of
the follow-up period (week 10)
 Change in visual acuity from baseline to week 3
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change in visual acuity (a change of 0.125 LogMAR
units or more) at weeks 3, 6 and 10
 Proportion of change in visual acuity [9] at weeks 3,
6 and 10
 Change in binocular functions from baseline to week
6/week 10
 Proportion of patients reporting outcomes in each
item of the patient satisfaction questionnaire
 Percentage compliance with treatment
 Proportion and type of adverse event
Proportion of change is measured as follows:
Proportion of change ¼ VAas−VAae=VAas−VAfe
VAas is vision of amblyopic eye at baseline, VAae is vision
of amblyopic eye at the ‘end of treatment’ and VAfe is the
vision of the non-amblyopic eye at the’ end of treatment’
[9]. ‘End of treatment’ is the time point the change is be-
ing measured up to, that is, weeks 3, 6 and 10.Safety assessment
All adverse events will be recorded. They will be
categorised according to whether they are device related
according to the Figure 2.
Events which could be considered to be anticipated
due to the hypothesised mechanism of action of the
treatment include nausea, photosensitive epilepsy, head-
ache, diplopia and reverse amblyopia. None of these
events have been observed in previous studies.Sample size
Assuming a standard deviation (SD) of 0.25 [8], 25 pa-
tients per arm would be required to detect a minimum
difference of 0.2 LogMAR units at the 5% significance
level (two-sided) with 80% power. Therefore a total of
75 patients would be required.Adverse events Non-device related
Non-serious Adverse event (AE)
Serious Serious Adverse Even
(SAE)
A
Figure 2 Classification of adverse effects.Statistical methods
The primary endpoint is considered confirmatory with
secondary endpoints considered supportive.
The primary analyses will be performed on the
intention-to-treat (ITT) population. Supportive analyses
may be performed on a per protocol (PP) population de-
fined prior to code-break.
Except where a patient has been withdrawn from the
study or otherwise documented, all missing data will be
assumed to be missing completely at random (MCAR).
The primary analyses will not use any imputation methods
to compensate for missing data.
There will be two primary comparisons: I-BiT™ games vs.
non-I-BiT™ games and I-BiT™ DVD vs. I-BiT™ games. Both
these analyses will comprise ANCOVA using baseline vis-
ual acuity as a co-variate, where distributional assumptions
are met. If these assumptions are not met, a suitable trans-
formation will be applied or a non-parametric method
used. There will be no correction for multiplicity.
Summary statistics including mean, median, SD and
95% confidence intervals will be provided, in addition to
appropriate graphical displays.
All datasets will be defined in a blinded manner prior
to database lock.
Further details of the statistical analyses will be pro-
vided in the statistical analysis plan which will be
finalised prior to database lock.Monitoring
No data monitoring committee will be appointed for this
study due to the expected low incidence of adverse events.
Routine data monitoring will be performed in accordance
with the sponsor’s standard operating procedures.Ethical considerations
The study has received approval from both the Research
Ethics Committee and Medicines and Health Regulatory
Authority (MHRA) and will be conducted in accordance
with the Declaration of Helsinki, ICH GCP and ISO14155.Device of procedure related
Adverse Device Effect (ADE)
Serious Adverse Device Effect (SADE)
Anticipated Unanticipated
Anticipated Serious 
dverse Device Effect 
(ASADE)
Unanticipated Serious 
AdverseDevice Effect  
(USADE)
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This is the first randomised controlled study using the
I-BiT™ system. It aims to determine whether the im-
provements in visual acuity observed in previous, uncon-
trolled studies of I-BiT™ technology are maintained under
strict clinical trial conditions. It also aims to determine
whether there is a difference between playing games and
watching DVDs using I-BiT™ technology, and whether
there is a difference between playing games using and not
using the I-BiT™ technology and therefore identify which
is the optimal treatment to develop.
Compliance is a huge issue with conventional patching
treatment which impacts on the efficacy of the treatment.
Therefore this study also aims to determine the compli-
ance of patients undergoing each of the treatments.
The study also aims to determine whether there are any
adverse effects which could be related to I-BiT™. It has
been hypothesised that there is a theoretical risk of ad-
verse events such as nausea, photosensitive epilepsy, head-
ache, diplopia and reverse amblyopia. However, none of
these events have been observed in previous studies.
It has not been possible to fully blind the study. How-
ever, the masking procedures ensure that clinical assess-
ments are made in a blinded manner and therefore
should not be subject to bias. The treating orthoptist will
have no access to assessment results either through the
database or through medical notes and indeed controls
are in place to ensure that the treating orthoptist cannot
treat these patients after they complete the study and
thereby gain access to their resultant visual acuity
measurement.
This study looks specifically at patients between the
ages of 4 and 8 years. Cleary et al. [10] found improve-
ments in older children in a pilot study with an I-BiT™
prototype system. Therefore it is possible that improve-
ments could be gained in patients older than 8 years
with the current I-BiT™ system. However, there are no
plans formally assess this at present, the priority being
to develop an optimal treatment regimen for children.
The results of this study will inform further development.
It will be necessary to determine an optimal treatment
regimen which may involve more frequent visits or a larger
number of treatments in order to provide a long-term
effect. It will also be necessary to follow-up patients in the
longer term to ensure maintenance of beneficial effects.
If I-BiT™ is shown to be an effective treatment for
amblyopia there is great potential for developing this
treatment in a number of settings. While making available
in hospital orthoptic clinics, there is also the potential that
it could be used in high street opticians throughout
Europe and even the potential to develop a home-based
treatment regimen. There is therefore the opportunity to
make improvements in both vision and quality of life for
children, but to also decrease treatment costs.Trial status
As of 6 November 2012, 21 patients have been randomised.
Recruitment will continue until 75 patients are randomised.
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